Chen Caoyang, Feng Yuqian, Ko Frankie Chi Fat, Lam Sze Kwan, Yan Sheng, Ho James Chung Man
Department of Cardiothoracic Surgery, Wuhan Fourth Hospital, Wuhan, Hubei, China.
Division of Respiratory Medicine, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hongkong, Hong Kong SAR, China.
Front Oncol. 2025 Jun 12;15:1597585. doi: 10.3389/fonc.2025.1597585. eCollection 2025.
Metastasis to mediastinal lymph nodes signifies an advanced stage of non-small cell lung cancer (NSCLC) and presents significant clinical challenges. Cancer-associated fibroblasts (CAFs) within the tumor microenvironment (TME) play a crucial role in tumor progression by promoting growth and invasion. However, the specific contributions of lung CAFs to mediastinal lymph node metastasis in NSCLC remain poorly understood. Moreover, no therapeutics currently target CAFs to combat mediastinal lymph node metastasis in NSCLC. This study aims to elucidate the precise roles of CAFs in these complex processes and to investigate innovative therapeutic strategies that target CAFs to suppress metastasis to mediastinal lymph nodes.
Normal human lung fibroblasts (MRC-5) were directly co-cultured with NSCLC cell lines (H358 and HCC827) to generate lung CAFs. These activated CAFs were identified using immunofluorescence, flow cytometry, and Western blotting. To model human mediastinal lymph node metastasis, orthotopic xenograft (OX) models were established by intrathoracically injecting NSCLC cells into the left lung of mice, either alone or in combination with lung CAFs. The viability of cancer cells and lung CAFs post-treatment with ABT-199, a Bcl-2 inhibitor, was evaluated using MTT assays. The therapeutic efficacy of ABT-199 was further assessed through oral gavage in OX models, focusing on its potential to prevent metastasis to mediastinal lymph nodes. Tumor growth was monitored longitudinally using micro-computed tomography (CT), and treatment response was evaluated in accordance with RECIST 1.1 criteria. Primary tumors and mediastinal lymph node metastases were analyzed using hematoxylin and eosin (H&E) staining for general morphology, supplemented by immunohistochemistry/immunofluorescence to detect specific protein markers. Fibrillar collagen deposition within the TME was quantified using picrosirius red staining (PRS).
Activation of α-SMA, accompanied by a significant increase in Col 1A1 expression in MRC-5 cells, was successfully induced through a direct 14-day co-culture with NSCLC cell lines. Histological analysis revealed increased fibrotic tissue formation, enhanced fibrillar collagen deposition, peritumoral lymphangiogenesis, and mediastinal lymph node metastasis in CAFs-enriched orthotopic xenograft (OX) tumors compared to CAFs-devoid OX tumors. The viability of lung CAFs was dose-dependently inhibited by ABT-199 . A two-week treatment with ABT-199 (100mg/kg) led to a significant reduction in lung CAFs and lymphangiogenesis in the CAFs-enriched OX model. Furthermore, an eight-week treatment with ABT-199 (100mg/kg) significantly reduced fibrillar collagen deposition and inhibited the number of metastases to mediastinal lymph nodes in both CAFs-devoid and CAFs-enriched OX models.
In NSCLC, cancer cells induce the differentiation of resident normal lung fibroblasts into lung CAFs. These CAFs secrete excessive collagens within the TME, thereby promoting tumor lymphangiogenesis and facilitating metastasis to mediastinal lymph nodes. Our findings, based on modified OX models, suggest that targeting lung CAFs could effectively attenuate lymphatic dissemination in NSCLC.
纵隔淋巴结转移意味着非小细胞肺癌(NSCLC)进入晚期,带来了重大的临床挑战。肿瘤微环境(TME)中的癌症相关成纤维细胞(CAFs)通过促进肿瘤生长和侵袭,在肿瘤进展中发挥关键作用。然而,肺CAFs对NSCLC纵隔淋巴结转移的具体作用仍知之甚少。此外,目前尚无针对CAFs来对抗NSCLC纵隔淋巴结转移的治疗方法。本研究旨在阐明CAFs在这些复杂过程中的精确作用,并研究针对CAFs以抑制纵隔淋巴结转移的创新治疗策略。
将正常人肺成纤维细胞(MRC-5)与NSCLC细胞系(H358和HCC827)直接共培养以生成肺CAFs。使用免疫荧光、流式细胞术和蛋白质印迹法鉴定这些活化的CAFs。为模拟人类纵隔淋巴结转移,通过将NSCLC细胞单独或与肺CAFs联合经胸腔内注射到小鼠左肺中建立原位异种移植(OX)模型。使用MTT法评估用Bcl-2抑制剂ABT-199处理后癌细胞和肺CAFs的活力。通过在OX模型中口服灌胃进一步评估ABT-199的治疗效果,重点关注其预防纵隔淋巴结转移的潜力。使用微型计算机断层扫描(CT)纵向监测肿瘤生长,并根据RECIST 1.1标准评估治疗反应。使用苏木精和伊红(H&E)染色分析原发性肿瘤和纵隔淋巴结转移灶的一般形态,并辅以免疫组织化学/免疫荧光检测特定蛋白质标志物。使用天狼星红染色(PRS)定量TME内的纤维状胶原沉积。
通过与NSCLC细胞系直接共培养14天,成功诱导了MRC-5细胞中α-SMA的活化,同时Col 1A1表达显著增加。组织学分析显示,与不含CAFs的OX肿瘤相比,富含CAFs的原位异种移植(OX)肿瘤中纤维化组织形成增加、纤维状胶原沉积增强、肿瘤周围淋巴管生成增加以及纵隔淋巴结转移增加。ABT-199对肺CAFs的活力具有剂量依赖性抑制作用。在富含CAFs的OX模型中,用ABT-199(100mg/kg)进行为期两周的治疗导致肺CAFs和淋巴管生成显著减少。此外,在不含CAFs和富含CAFs的OX模型中,用ABT-199(100mg/kg)进行为期八周的治疗均显著减少了纤维状胶原沉积并抑制了纵隔淋巴结转移的数量。
在NSCLC中,癌细胞诱导驻留的正常肺成纤维细胞分化为肺CAFs。这些CAFs在TME内分泌过多的胶原蛋白,从而促进肿瘤淋巴管生成并促进向纵隔淋巴结的转移。我们基于改良OX模型的研究结果表明,靶向肺CAFs可有效减轻NSCLC中的淋巴扩散。